- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Instagram Pages
Here you can access stories featured on our instagram page. Want more biosimilar news? Sign up for our weekly newsletter, delivered to your inbox every Wednesday here.
More Research Finds Low Awareness of Biosimilars Among Oncology Providers
NHS Provides Update on Biosimilar Adalimumab With a Focus on ISRs
ye on Pharma: Biocon Reports Its Highest-Ever Revenue and Profit Growth for Q3
eview Points to Nocebo Effect as a Cause of Higher Discontinuation Rates for Biosimilars
Coherus Settles With AbbVie, Sues Amgen, Over Biosimilar Adalimumab
ncreases in Insulin Prices Drove Spending Over 4 Years, Report Says
uropean Report Says M&As Affecting Biosimilars Need Scrutiny
Drugs Targeted by Biosimilars Are Responsible for Some of the Highest Hospital Spending
Sanctions Against Samsung BioLogics Suspended Pending Court Ruling
ales of Oncology Reference Products Far Outpace R&D Costs, Study Finds
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
